3Suppliers
14Customers
1Debt Items
20Related Chains

Viatris Inc. Suppliers

TickerNameConfidenceEvidence
MAPI MAPI 92% In December 2023, the Company entered into a letter agreement, as amended, with Mapi for the development and commercialization of certain additional products.
ORANY ORANY 72% ry, and the time required for approval may be longer or shorter than that required in the U.S. Bioequivalence, clinical, or other studies conducted in one country may not be accepted in other countri…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from VTRS graph: ry, and the time required for approval may be longer or shorter than that required in the U.S. Bioequivalence, clini…

Viatris Inc. Customers

TickerNameConfidenceEvidence
CENCORA-INC-FORMERLY-AMERISOURCEBERGEN-CORPORATI CENCORA-INC-FORMERLY-AMERISOURCEBERGEN-CORPORATI 90% Percentage of Consolidated Net Sales 2024 2023 2022 Cencora, Inc. (formerly AmerisourceBergen Corporation) 12 % 10 % 10 %
CAH Cardinal Health, Inc. 72% posal & impairment charges ( ) Impairment of goodwill ( ) Research and development ( ) Acquired IPR&D ( ) Litigation settlements and other contingencies, net ( ) Transaction related and other special…
CAH Cardinal Health, Inc. 72% Reciprocal relationship from CAH graph: Reciprocal relationship from VTRS graph: Reciprocal relationship from CAH graph: Reciprocal relationship from VTRS graph: Reciprocal relationship from CAH grap…
MCK McKesson Corporation 72% Reciprocal relationship from MCK graph: Reciprocal relationship from VTRS graph: Reciprocal relationship from MCK graph: Reciprocal relationship from VTRS graph: Reciprocal relationship from MCK grap…
MCK McKesson Corporation 72% Item 1A Risk Factors - “ The pharmaceutical industry is heavily regulated, and we face significant costs and uncertainties associated with our efforts to comply with applicable laws and regulations. …
ORANY ORANY 72% dose estrogen weekly patch for contraception and fast-absorbing formulation of meloxicam. Product development is inherently risky, especially for new drugs for which safety and efficacy have not been…
ORANY ORANY 72% Reciprocal relationship from ORANY graph: Reciprocal relationship from VTRS graph: dose estrogen weekly patch for contraception and fast-absorbing formulation of meloxicam. Product development is inh…
AMERISOURCEBERGEN-CORPORATION AMERISOURCEBERGEN-CORPORATION 62% Item 1A Risk Factors - “ The pharmaceutical industry is heavily regulated, and we face significant costs and uncertainties associated with our efforts to comply with applicable laws and regulations. …
MATRIX-PHARMA-PRIVATE-LIMITED MATRIX-PHARMA-PRIVATE-LIMITED 62% ty The ¥40 billion term loan agreement dated as of July 1, 2021, among Viatris, the guarantors from time to time party thereto, the lenders from time to time party thereto and Mizuho Bank, Ltd., as a…
MIZUHO-BANK-LTD MIZUHO-BANK-LTD 62% ty The ¥40 billion term loan agreement dated as of July 1, 2021, among Viatris, the guarantors from time to time party thereto, the lenders from time to time party thereto and Mizuho Bank, Ltd., as a…
MYLAN-SECURITIZATION-LLC MYLAN-SECURITIZATION-LLC 62% value option for the CCPS under ASC 825. The fair value is reassessed quarterly and any change in the fair value estimate is recorded in Other Expense (Income), Net in the consolidated statements of …
ROCHESTER-DRUG-COMPANY ROCHESTER-DRUG-COMPANY 62% commercialization in the partnered regions, including pre- and post-launch activities and product registration and all associated costs. Under the terms of the agreements, Theravance Biopharma is eli…
SENIOR-UNSECURED-NOTES-VIATRIS-INC SENIOR-UNSECURED-NOTES-VIATRIS-INC 62% value option for the CCPS under ASC 825. The fair value is reassessed quarterly and any change in the fair value estimate is recorded in Other Expense (Income), Net in the consolidated statements of …
THERAMEX-HQ-UK-LIMITED THERAMEX-HQ-UK-LIMITED 62% ty The ¥40 billion term loan agreement dated as of July 1, 2021, among Viatris, the guarantors from time to time party thereto, the lenders from time to time party thereto and Mizuho Bank, Ltd., as a…

Viatris Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
VTRS-DEBT Debt stack $14.6B 90% Market cache reports total debt of $14.6B.

Viatris Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Viatris Inc..

Viatris Inc. Ownership

HolderNameConfidenceEvidence
VTRS-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC VANGUARD CAPITAL MANAGEMENT LLC 90% 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 1022 tracked holders.

Viatris Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
HLN Haleon plc 100.00 2
LOW Lowe's Companies, Inc. 100.00 2
HLNCF Haleon plc 100.00 2
GRDN Guardian Pharmacy Services, Inc. 100.00 2
MASI Masimo Corporation 100.00 2
APT Alpha Pro Tech, Ltd. 100.00 2
ORANY ORANGE 100.00 1 ['customer', 'supplier']
ARDX Ardelyx, Inc. 100.00 2
GILD Gilead Sciences, Inc. 100.00 2
HALO Halozyme Therapeutics, Inc. 100.00 2
CVS CVS Health Corporation 100.00 2
HRMY Harmony Biosciences Holdings, Inc. 100.00 2
MGNX MacroGenics, Inc. 100.00 2
SCLX Scilex Holding Company 100.00 2
CHRS Coherus Oncology, Inc. 100.00 2
REGN Regeneron Pharmaceuticals, Inc. 100.00 2
CAH Cardinal Health, Inc. 100.00 1 ['customer']
CLH Clean Harbors, Inc. 100.00 2
EMMA Emmaus Life Sciences, Inc. 100.00 2
MCK McKesson Corporation 100.00 1 ['customer']